Payment overview · 2025
General Payments
$567.06
23 reported records · 9 companies
Healthcare provider profile · identity verified
David Smith Oyer, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · CHICAGO, IL · NPI 1134226467
Verified facts
What the public records show
CMS Open Payments records show David Smith Oyer, M.D. received $567.06 in general payments during 2025 across 23 reported records.
Novo Nordisk Inc accounted for 46.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Ozempic.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $265.25 | 46.8% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.02 | 9.7% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $47.04 | 8.3% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 7.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.86 | 7.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.64 | 7.0% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.82 | 5.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.93 | 4.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.00 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $427.75 | 19 |
| Education | $139.31 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $103.05 | 7 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $47.04 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $39.64 | 2 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $32.82 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.83 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.33 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.57 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 110 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 231 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
231 | 65 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 327 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 291 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 266 | 82 |
| Ozempic | Semaglutide | 231 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 225 | 51 |
| Ezetimibe | Ezetimibe | 191 | 65 |
| Losartan Potassium | Losartan Potassium | 184 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 156 | 39 |
| Jardiance | Empagliflozin | 110 | 28 |
| Synthroid | Levothyroxine Sodium | 90 | 20 |
| Irbesartan | Irbesartan | 87 | 22 |
| Tresiba Flextouch U-100 | Insulin Degludec | 82 | 26 |
| Mounjaro | Tirzepatide | 79 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 16 |
| Eliquis | Apixaban | 73 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | suppressed |
| Simvastatin | Simvastatin | 69 | 21 |
| Eplerenone | Eplerenone | 67 | 18 |
| Xarelto | Rivaroxaban | 64 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 62 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 61 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 61 | 19 |
| Lorazepam | Lorazepam | 60 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 18 |
| Metformin Hcl Er | Metformin Hcl | 55 | 17 |
| Azithromycin | Azithromycin | 54 | 40 |
| Lisinopril | Lisinopril | 51 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 50 | 16 |
| Alprazolam | Alprazolam | 49 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 49 | 23 |
| Tresiba Flextouch U-200 | Insulin Degludec | 49 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 15 |
| Dofetilide | Dofetilide | 46 | suppressed |
| Gabapentin | Gabapentin | 43 | 14 |
| Terazosin Hcl | Terazosin Hcl | 43 | suppressed |
| Celecoxib | Celecoxib | 42 | 15 |
| Valacyclovir | Valacyclovir Hcl | 42 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 11 |
| Furosemide | Furosemide | 40 | 11 |
| Metformin Hcl | Metformin Hcl | 40 | 11 |
| Diazepam | Diazepam | 38 | 12 |
| Omeprazole | Omeprazole | 38 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 13 |
| Glimepiride | Glimepiride | 37 | 12 |
| Allopurinol | Allopurinol | 36 | suppressed |
| Valsartan | Valsartan | 36 | 11 |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Ramipril | Ramipril | 33 | suppressed |
| Carvedilol | Carvedilol | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 15 |
| Temazepam | Temazepam | 30 | 14 |
| Colchicine | Colchicine | 29 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Cephalexin | Cephalexin | 27 | 16 |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 14 |
| Clonazepam | Clonazepam | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Humalog | Insulin Lispro | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 16 |
| Prednisone | Prednisone | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 11 |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Sumatriptan | Sumatriptan | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $567.06 · 23 records | Novo Nordisk Inc | AFREZZA, Cologuard Collection Kit, GVOKE HYPOPEN, JARDIANCE, Kerendia, OTEZLA, Omnipod, Ozempic, REPATHA, Rybelsus, STRENSIQ, The Cologuard Plus Collection Kit, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error